Tropical Journal of Pharmaceutical Research

Original Research Article | OPEN ACCESS

Bryostatin 1 alleviates respiratory syncytial virus pneumonia in a mice model via down-regulation of inflammatory cytokines

Feng Xu¹, Jun Chen¹, Beizheng Xu², Haiyan Liu¹, Jian Song¹, Aili Zhang³

¹Respiration Department, Cangzhou People's Hospital, Cangzhou, Hebei-061000; ²Clinical Medicine, Tianjin Medical University, Tianjin-300070; ²Respiration Department, Hebei General Hospital, Shijiazhuang, Hebei 050051, China;

For correspondence:- Aili Zhang Email: zhangaili485@sina.com Tel:+8618632138878

Accepted: 19 November 2019 Published: 31 December 2019

Citation: Xu F, Chen J, Xu B, Liu H, Song J, Zhang A. Bryostatin 1 alleviates respiratory syncytial virus pneumonia in a mice model via down-regulation of inflammatory cytokines. Trop J Pharm Res 2019; 18(12):2583-2589 doi: 10.4314/tjpr.v18i12.18

© 2019 The authors.
This is an Open Access article that uses a funding model which does not charge readers or their institutions for access and distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/4.0) and the Budapest Open Access Initiative (http://www.budapestopenaccessinitiative.org/read), which permit unrestricted use, distribution, and reproduction in any medium, provided the original work is properly credited..

Abstract

Purpose: To investigate the effect of bryostatin 1 on respiratory syncytial virus (RSV) infection in vitro in lung alveolar cells and in vivo in a mice model.

Methods: RSV infection in the mice was induced by the administration of 2 x 106 PFU viral particles intranasally in the left nostril. Reverse transcription-polymerase chain reaction (RT-PCR) and western blotting were used for the determination of changes in interleukin expression.

Results: Bryostatin 1 treatment of RSV-infected BEAS-2B cells significantly (p < 0.05) inhibited viability. The mortality of mice infected with RSV markedly decreased on treatment with bryostatin 1. The pulmonary damage induced by RSV infection was also prevented in mice treated with bryostatin 1. Treatment of the RSV infected mice with bryostatin 1 caused a dose-based suppression of IL 1β/ 18 and TNF α generation (p < 0.05). Bryostatin 1 pre-treatment at doses 2, 6 and 12 mg/kg led to reduction of NLRP3, ASC and caspase 1 proteins, as well as a significant decrease in the expression of mRNA corresponding to NLRP3, ASC and caspase 1 (p< 0.05).

Conclusion: The results demonstrate that bryostatin 1 treatment of RSV-infected BEAS-2B cells prevents reduction in its viability. Moreover, pre-treatment of RSV-infected mice with bryostatin 1 improves mortality and prevents pulmonary tissue damage by down-regulating NLRP3 activation. Therefore, bryostatin 1 may be an option for the development of an effective treatment for pneumonia.

Keywords: Pneumonia, Pharyngitis, Inflammasome, Inflammatory cytokine